A recent study published in the Proceedings of the National Academy of Sciences found that the use of immunotoxins in the mammary gland eliminates visible and invisible lesions in patients.
The study was conducted in a laboratory and led by researchers at the Johns Hopkins Kimmel Cancer Center, which is best known for its early breast cancer.
The zero stage of the disease, also known as DCIS (ductal carcinoma in situ), is characterized by the presence of malignant cells in the milk ducts.
According to the study’s lead author, Saraswati Sukumar, most women undergo radiation surgery, radiation treatment and, in some cases, chemotherapies or hormones to treat early cancer.
“In our research, we have provided additional treatment by which an immunotoxin injection through this channel can eliminate DCIS,” Sukumar said in a statement.
First, this work assessed the potency of immunotoxins in four different types of breast cancer cells in mice. The results showed that the treatment resulted in the death of tumor cells in both of them.
The researchers also administered the drug to about 10 mice to extract contaminants that could spread through the bloodstream after an intervention, and 5 to 30 minutes later, they found nothing.
He then injected the immunotoxin directly into the two groups of mice with DCIS, known as MCF7 AND SUM225.
Initially, it was given once a week for three weeks and, to match favoritism, was used on the body of other mice.
At the end of treatment, she was found to have received a small injection into her body, but she returned empty-handed.
Those who received it directly in the ducts were tumors completely eliminated within two weeks after treatment and the structure of the breast was similar to normal mammary glands. No recurrence was reported after two months.
The SUM225 team suppressed the disease in just two weeks of treatment and did not show any recurrence until the end of the study.
According to the authors, the drug was well tolerated, with no toxic effects or injections. He added that the study provides a solid basis for conducting feasible and safe tests for patients with stage 0 breast cancer.
According to reports from the Inca (National Cancer Institute), last year, Brazil had 66,300 cases of the disease in women, and 17,800 deaths. Breast cancer is the most common cancer in women in all parts of the world, after non-melanoma skin cancer.
Breastfeeding is free. Learn all about breast cancer